<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02130414</url>
  </required_header>
  <id_info>
    <org_study_id>CYC102</org_study_id>
    <nct_id>NCT02130414</nct_id>
  </id_info>
  <brief_title>PK, Safety &amp; Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects</brief_title>
  <acronym>CYC102</acronym>
  <official_title>A Multiple Dose, Multi-stage Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Colon Tissue Distribution of Cyclosporine Capsules (CyCol®) Compared to Intravenous Cyclosporine in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sigmoid Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sigmoid Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this Phase I, single centre, multi stage study is to evaluate the safety,&#xD;
      tolerability, pharmacokinetics and relative colonic mucosal concentrations of cyclosporine&#xD;
      capsules (CyCol®) compared to intravenous cyclosporine in healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multiple-dose, multi-stage pharmacokinetic (PK) study. A maximum of 40&#xD;
      healthy adult male volunteers aged between 18 and 55 years will be enrolled at a single&#xD;
      clinical research unit.&#xD;
&#xD;
      For each CyCol® group dosing will last 7 days, whilst the Sandimmun® IV group will have a&#xD;
      single dose over 24 hours.&#xD;
&#xD;
      Single dose pharmacokinetics of different doses of CyCol® will be compared to IV Sandimmun®.&#xD;
      In addition colonic tissue concentrations will be compared after multiple doses of CyCol® to&#xD;
      a single IV dose of Sandimmun®. Concentrations of unchanged cyclosporine and it's metabolites&#xD;
      in the faeces will also be explored.&#xD;
&#xD;
      Stage 1 of the study will investigate the 75mg dose (OD and BID) of CyCol® and IV Sandimmun®.&#xD;
      Then dependent on results Stages 2 and 3 will investigate either lower (37.5mg) or higher&#xD;
      (150mg) dose levels. The dosing regimens chosen for Stages 2 and 3 will be based upon safety&#xD;
      and tolerability, systemic exposure and colonic mucosa tissue concentrations observed at&#xD;
      other doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic variables for cyclosporine (in whole blood)</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Area under the concentration-time curve (AUC) from;&#xD;
time zero to the last non-zero concentration (AUC 0-t),&#xD;
time zero extrapolated to infinity (AUC 0-inf),&#xD;
maximum observed concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations (ng/g) of cyclosporine and its metabolites (AM1, AM9, AM4N) in colonic mucosa</measure>
    <time_frame>Day 2 or Day 7</time_frame>
    <description>Concentrations (ng/g) of cyclosporine and its metabolites (AM1, AM9, AM4N)in colonic mucosal tissue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of CyCol</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Percentage of subjects with clinically significant abnormal results</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Amount of unchanged cyclosporine and its metabolites excreted in faeces</measure>
    <time_frame>Day 1 through Day 7</time_frame>
    <description>To evaluate the amount (ng/g) of unchanged cyclosporine and its metabolites (AM1, AM9, AM4N) excreted in the faeces.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sandimmun® IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sandimmun® IV 2mg/kg as a 24 hour infusion (2mg/kg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CyCol® capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CyCol®: 75 mg OD &amp; BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CyCol® capsules 37.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CyCol®: 37.5 mg OD or BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CyCol® capsules, 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CyCol®: 150 mg OD or BID for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sandimmun® IV</intervention_name>
    <description>2 mg/kg IV</description>
    <arm_group_label>Sandimmun® IV</arm_group_label>
    <other_name>Cyclosporine A</other_name>
    <other_name>Sandimmun® concentrate for solution for Infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CyCol® capsules</intervention_name>
    <description>37.5 mg CyCol® capsules</description>
    <arm_group_label>CyCol® capsules</arm_group_label>
    <arm_group_label>CyCol® capsules 37.5 mg</arm_group_label>
    <arm_group_label>CyCol® capsules, 150 mg</arm_group_label>
    <other_name>Cyclosporine A</other_name>
    <other_name>oral cyclosporine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers, between the ages of 18 and 55 years, inclusive.&#xD;
&#xD;
          -  Mass Index (BMI) of 18.5 to 30.0 kg/m2, inclusive; and a total body weight &gt;50 kg (110&#xD;
             lbs).&#xD;
&#xD;
          -  Subjects capable of providing written consent.&#xD;
&#xD;
          -  Subjects willing to use acceptable method of contraception starting from the first&#xD;
             dose and continuing for at least 3 months after the last dose of study drug.&#xD;
&#xD;
          -  Subjects who are willing and able to comply with scheduled visits, dosing plan,&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
          -  Subjects must have a regular bowel movement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, gastrectomy).&#xD;
&#xD;
          -  A positive urine drug screen.&#xD;
&#xD;
          -  History of significant drug abuse&#xD;
&#xD;
          -  History of regular alcohol consumption&#xD;
&#xD;
          -  Treatment with an investigational drug within 90 days prior to first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  If considered clinically significant by the Investigator, screening supine blood&#xD;
             pressure 140 mm Hg (systolic) or 90 mm Hg (diastolic), on a single measurement&#xD;
             (confirmed by a single repeat, if necessary) following at least 5 minutes of rest.&#xD;
&#xD;
          -  12-lead ECG demonstrating QTcF interval &gt;450 msec or a QRS interval &gt;120 msec at&#xD;
             Screening.&#xD;
&#xD;
          -  Use of medications :&#xD;
&#xD;
               -  prescription medications (oral and topical) within 14 days prior to first dosing.&#xD;
&#xD;
               -  over-the-counter products including herbal and food supplements within 7 days&#xD;
                  prior to first dose of study medication&#xD;
&#xD;
               -  injection or implant of any drug within 3 months prior to first dose of study&#xD;
                  medication&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days&#xD;
             prior to administration of the study medication.&#xD;
&#xD;
          -  Plasma donation within 7 days prior to dosing.&#xD;
&#xD;
          -  History of sensitivity to cyclosporine or other related drugs.&#xD;
&#xD;
          -  Subjects with evidence of ongoing (active or carrier status) hepatitis B or C, or&#xD;
             human immunodeficiency virus (HIV) infection upon serological testing.&#xD;
&#xD;
          -  History of latent or active tuberculosis or exposure to endemic areas within 8 weeks&#xD;
             prior to Quantiferon test performed at screening.&#xD;
&#xD;
          -  Positive Quantiferon test result&#xD;
&#xD;
          -  Subjects who have received or are planning to receive any live virus vaccination&#xD;
             within 28 days prior to the first dose of study medication, or planning to receive a&#xD;
             vaccination during the course of the study.&#xD;
&#xD;
          -  Any evidence of active infection or febrile illness within 7 days of the first dose of&#xD;
             study medication&#xD;
&#xD;
          -  Presence of fever (body temperature &gt;37.6oC) within 2 weeks prior to first dose of&#xD;
             study medication.&#xD;
&#xD;
          -  Subjects who are unwilling to refrain from consumption of grapefruit or products&#xD;
             containing grapefruit juice or grapefruit-related citrus fruits (eg, starfruit,&#xD;
             pomelos) from 7 days prior to the first dose of study medication until completion of&#xD;
             all study procedures.&#xD;
&#xD;
          -  Unwilling or unable to comply with the guidelines described in this protocol, or a&#xD;
             reason which, in the opinion of the Investigator, would prevent the subject from&#xD;
             participating in the study.&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation and, in the&#xD;
             judgment of the investigator, would make the subject inappropriate for entry into this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sigmoid Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Sigmoid Pharma</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>May 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2014</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cyclosporine</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>CyCol</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

